IDSIQ

WIPO WIPO 2020

Schützen Sie diese Marke vor Nachahmern!

Mit unserer Markenüberwachung werden Sie automatisch per E-Mail über Nachahmer und Trittbrettfahrer benachrichtigt.

Die Internationale Marke IDSIQ wurde als Wortmarke am 30.12.2020 bei der Weltorganisation für geistiges Eigentum angemeldet.

Markendetails Letztes Update: 31. Januar 2023

Markenform Wortmarke
Aktenzeichen 1584862
Registernummer 754999
Länder Australien Brasilien Kanada Europäische Gemeinschaft Großbritannien Israel Indien Island Japan Südkorea Mexiko Norwegen Neuseeland Singapur Türkei Vereinigte Staaten von Amerika (USA) China Liechtenstein Russland Ukraine
Basismarke CH Nr. 754999, 02. November 2020
Anmeldedatum 30. Dezember 2020
Ablaufdatum 30. Dezember 2030

Markeninhaber

Hegenheimermattweg 91
4123 Allschwil
CH

Markenvertreter

Waren und Dienstleistungen

09 Electronic publications (downloadable) in the field of medical tests which are used for identifying symptoms of insomnia in patients and the effects of insomnia disorders on patients or symptoms of mental disorders associated with insomnia in patients and the effects of mental disorders associated with insomnia disorders on patients and in the field of collection of medical data which are used for identifying symptoms of insomnia in patients and the effects of insomnia disorders on patients or symptoms of mental disorders associated with insomnia in patients and the effects of mental disorders associated with insomnia disorders on patients
16 Printed matter (publications) in the field of medical tests which are used for identifying symptoms of insomnia in patients and the effects of insomnia disorders on patients or symptoms of mental disorders associated with insomnia in patients and the effects of mental disorders associated with insomnia disorders on patients and in the field of collection of medical data which are used for identifying symptoms of insomnia in patients and the effects of insomnia disorders on patients or symptoms of mental disorders associated with insomnia in patients and the effects of mental disorders associated with insomnia disorders on patients
41 Multimedia publication of printed matter in the field of medical tests which are used for identifying symptoms of insomnia in patients and the effects of insomnia disorders on patients or symptoms of mental disorders associated with insomnia in patients and the effects of mental disorders associated with insomnia disorders on patients and in the field of collection of medical data which are used for identifying symptoms of insomnia in patients and the effects of insomnia disorders on patients or symptoms of mental disorders associated with insomnia in patients and the effects of mental disorders associated with insomnia disorders on patients; multimedia publication of printed matter in the field of tests which are used for identifying symptoms of insomnia in patients and the effects of insomnia disorders on patients or symptoms of mental disorders associated with insomnia in patients and the effects of mental disorders associated with insomnia disorders on patients and in the field of collection of medical data which are used for identifying symptoms of insomnia in patients and the effects of insomnia disorders on patients or symptoms of mental disorders associated with insomnia in patients and the effects of mental disorders associated with insomnia disorders on patients
42 Scientific research and development, namely pharmaceutical and medical testing services and development of pharmaceutical and medical tests which are used for identifying symptoms of insomnia in patients and the effects of insomnia disorders on patients or symptoms of mental disorders associated with insomnia in patients and the effects of mental disorders associated with insomnia disorders on patients; scientific research, namely analysis of objective data on patients by means of diagnostic tests in the context of drug administration, analysis of subjective data on patients by means of patient questioning, analysis of such data with the aim of optimizing drug treatments and drug administration
Die Bezeichnungen wurden automatisch übersetzt. Übersetzung anzeigen

Markenhistorie

Datum Belegnummer Bereich Eintrag
21. September 2022 2022/40 Gaz IS Ablehnung
19. September 2022 2023/5 Gaz SG RAW: Rule 18ter(2)(ii) GP following a provisional refusal
09. September 2022 2022/37 Gaz US RAW: Rule 18ter(2)(ii) GP following a provisional refusal
20. Juli 2022 2022/29 Gaz CA Ablehnung
04. Juli 2022 2022/27 Gaz MX Ablehnung
20. April 2022 2022/16 Gaz NO Ablehnung
01. April 2022 2022/14 Gaz LI Ablehnung
17. März 2022 2022/11 Gaz KR Ablehnung
10. Februar 2022 2022/6 Gaz JP Ablehnung
08. Februar 2022 2022/6 Gaz BR Ablehnung
03. Februar 2022 2022/5 Gaz UA Ablehnung
15. Dezember 2021 2021/50 Gaz GB Ablehnung
05. Dezember 2021 2021/49 Gaz IL Ablehnung
06. November 2021 2021/46 Gaz NO Ablehnung
02. November 2021 2021/44 Gaz NZ Ablehnung
20. Oktober 2021 2021/42 Gaz TR Ablehnung
11. Oktober 2021 2021/41 Gaz IN Ablehnung
25. August 2021 2021/35 Gaz EM Ablehnung
07. August 2021 2021/33 Gaz SG Ablehnung
05. August 2021 2021/31 Gaz CN Ablehnung
26. Juli 2021 2021/30 Gaz US Ablehnung
29. Juni 2021 2021/26 Gaz AU Ablehnung
14. Juni 2021 2021/24 Gaz RU Ablehnung
30. Dezember 2020 2021/12 Gaz CH Eintragung

ID: 141584862